Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor
This study is testing if adding a targeted medication called a CDK4/6 inhibitor to the hormone-blocking drug elacestrant works better than elacestrant alone. It aims to help patients with a common type of advanced breast cancer who have already tried similar treatments.
You may be able to join if you have ER-positive, HER2-negative advanced breast cancer with a specific gene mutation called ESR1, and you have previously received hormone therapy that included a CDK4/6 inhibitor.
Participants will be randomly placed into one of two groups to receive either elacestrant by itself or elacestrant combined with a CDK4/6 inhibitor. Your health and the cancer's response will be closely monitored through regular scans and check-ups.
The study is currently recruiting participants and takes place in Chicago, Illinois, United States.
- 1Tests a combination of hormone-blocking and targeted medications
- 2For advanced breast cancer patients who have already tried specific prior therapies
- 3Currently recruiting participants in Chicago, Illinois
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.